Clinical significance of FLC tests in patients without other evidence of hematologic disorder.
FLC
MGUS
Multiple Myeloma
PCD
Journal
Clinical and experimental medicine
ISSN: 1591-9528
Titre abrégé: Clin Exp Med
Pays: Italy
ID NLM: 100973405
Informations de publication
Date de publication:
24 Aug 2024
24 Aug 2024
Historique:
received:
02
07
2024
accepted:
18
08
2024
medline:
24
8
2024
pubmed:
24
8
2024
entrez:
24
8
2024
Statut:
epublish
Résumé
The clinical significance of an abnormal free light chain (FLC) test, performed due to unspecific complains in the absence of a known plasma cell dyscrasia (PCD) or lymphoproliferative disease (LPD), is not fully elucidated. We investigated the importance of an abnormal FLC ratio (FLC-R) in this setting. Patients registered in the Maccabi Healthcare Services database, tested for FLC during 2007-2023 without previously documented PCD/LPD or increased total protein (TP) level, were reviewed. Demographics, co-morbidities, and laboratory tests were recorded. FLC-R was defined as normal (0.26-1.65) or slightly (slAb 0.1-0.26/1.65-4), moderately (mAbn 0.1-0.05/4-8) and significantly abnormal (sigAb- < 0.05 or > 8). Factors associated with PCD/LPD and overall survival were identified. In total, 8,661 patients, 2,215 (25.6%) with abnormal FLC-R [2,090 (24.1%)-slAb, 65 (0.75%)-mAbn and 60 (0.7%)-sigAb], were analyzed. Almost none had anemia nor acute renal failure. 14% had concomitant increased immunoglobulins. Within a median follow-up of 52 months, 943 were diagnosed with PCD (816-MGUS, 127-MM/Amyloidosis/plasmacytoma) and 48 with LPD. Median time to PCD and LPD were 19 and 28 months. Multivariate analysis found slAb (HR = 1.8, CI95%:1.53-2.12, p < 0.001), mAbn (HR = 6.3, CI95%:4.16-9.53, p < 0.001), and sigAb FLC (HR = 10.4, CI95%:7.0-15.35, p < 0.001), to be associated with PCD/LPD diagnosis. Decreased IgG, increased IgA, and concomitant comorbidities predicted PCD, whereas increased IgM predicted LPD. Older age, male gender, anemia, decreased albumin, increased IgG and concomitant comorbidities, predicted shorter survival. Our large study emphasizes the independent clinical significance of abnormal FLC-R as a predictor of PCD/LPD diagnosis even in patients with normal TP level, promoting early detection of PCD/LPD.
Identifiants
pubmed: 39180586
doi: 10.1007/s10238-024-01471-4
pii: 10.1007/s10238-024-01471-4
doi:
Substances chimiques
Immunoglobulin Light Chains
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
198Informations de copyright
© 2024. The Author(s).
Références
Kyle RA, Rajkumar SV. Epidemiology of the plasma-cell disorders. Best Pract Res Clin Haematol. 2007;20:637–64.
doi: 10.1016/j.beha.2007.08.001
pubmed: 18070711
Rajkumar SV, Kyle RA, Therneau TM, Melton LJ, Bradwell AR, Clark RJ, et al. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood [Internet]. 2005;106:812–7.
doi: 10.1182/blood-2005-03-1038
pubmed: 15855274
Rögnvaldsson S, Love TJ, Thorsteinsdottir S, Reed ER, Óskarsson JÞ, Pétursdóttir Í, et al. Iceland screens, treats, or prevents multiple myeloma (iStopMM): a population-based screening study for monoclonal gammopathy of undetermined significance and randomized controlled trial of follow-up strategies. Blood Cancer J. 2021;11:1–13.
doi: 10.1038/s41408-021-00480-w
El-Khoury H, Alberge J-B, Barr H, Murphy C, Sakrikar DJ, Krause T, et al. High prevalence of monoclonal gammopathy in a population at risk: the first results of the promise study. Blood [Internet]. 2021;138:152.
doi: 10.1182/blood-2021-149868
Thorsteinsdóttir S, Gíslason GK, Aspelund T, Rögnvaldsson S, Óskarsson JÞ, Sigurðardóttir G, et al. Prevalence of smoldering multiple myeloma based on nationwide screening. Nat Med. 2023;29:467–72.
doi: 10.1038/s41591-022-02183-6
pubmed: 36747117
pmcid: 11099842
El-Khoury H, Lee DJ, Alberge JB, Redd R, Cea-Curry CJ, Perry J, et al. Prevalence of monoclonal gammopathies and clinical outcomes in a high-risk US population screened by mass spectrometry: a multicentre cohort study. Lancet Haematol [Internet]. 2022;9:e340–9.
doi: 10.1016/S2352-3026(22)00069-2
pubmed: 35344689
Singh MK, Gupta P, Kumar K, Chandra D, Rahman K, Gupta R, et al. A comparative analysis of freelite and N Latex FLC assay for the sFLC measurements in suspected patients of monoclonal gammopathy. Indian J Hematol Blood Transfus. 2024.
Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. International Myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15:e538–48.
doi: 10.1016/S1470-2045(14)70442-5
pubmed: 25439696
Kyle RA, Durie BGM, Rajkumar SV, Landgren O, Blade J, Merlini G, et al. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia. 2010;24:1121–7.
doi: 10.1038/leu.2010.60
pubmed: 20410922
pmcid: 7020664
R Core Team. R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria, 2022. URL https://www.R-project.org/ .
Mikhael J, Bhutani M, Cole CE. Multiple myeloma for the primary care provider: a practical review to promote earlier diagnosis among diverse populations. Am J Med. 2023;136:33–41.
doi: 10.1016/j.amjmed.2022.08.030
pubmed: 36150517
Go RS, Vincent Rajkumar S. How I manage monoclonal gammopathy of undetermined significance. Blood [Internet]. 2018;131:163–73. https://doi.org/10.1182/blood-2017-09-807560 .
doi: 10.1182/blood-2017-09-807560
pubmed: 29183887
Go RS, Gundrum JD, Neuner JM. Determining the clinical significance of monoclonal gammopathy of undetermined significance: a SEER–medicare population analysis. Clin Lymphoma Myeloma Leuk. 2015;15:177-186.e4.
doi: 10.1016/j.clml.2014.09.004
pubmed: 25445471
Castillo JJ, Callander NS, Baljevic M, Sborov DW, Kumar S. The evaluation and management of monoclonal gammopathy of renal significance and monoclonal gammopathy of neurological significance. Am J Hematol [Internet]. 2021;96:846.
doi: 10.1002/ajh.26155
pubmed: 33709474
Sigurdardottir EE, Turesson I, Lund SH, Lindqvist EK, Mailankody S, Korde N, et al. The role of diagnosis and clinical follow-up of monoclonal gammopathy of undetermined significance on survival in multiple myeloma. JAMA Oncol [Internet]. 2015;1:168–74.
doi: 10.1001/jamaoncol.2015.23
pubmed: 26181017
Goyal G, Rajkumar SV, Lacy MQ, Gertz MA, Buadi FK, Dispenzieri A, et al. Impact of prior diagnosis of monoclonal gammopathy on outcomes in newly diagnosed multiple myeloma. Leukemia [Internet]. 2019;33:1273.
doi: 10.1038/s41375-019-0419-7
pubmed: 30787429
Sigurdardottir EE, Turesson I, Lund SH, Lindqvist EK, Mailankody S, Korde N, et al. The role of diagnosis and clinical follow-up of monoclonal gammopathy of undetermined significance on survival in multiple myeloma. JAMA Oncol [Internet]. 2015;1:168–74.
doi: 10.1001/jamaoncol.2015.23
pubmed: 26181017
Yong K, Delforge M, Driessen C, Fink L, Flinois A, Gonzalez-McQuire S, et al. Multiple myeloma: patient outcomes in real-world practice. Br J Haematol [Internet]. 2016;175:252–64.
doi: 10.1111/bjh.14213
pubmed: 27411022
Levraut M, Gavoille A, Landes-Chateau C, Cohen M, Bresch S, Seitz-Polski B, et al. Kappa free light chain index predicts disease course in clinically and radiologically isolated syndromes. neurol neuroimmunol neuroinflamm [Internet]. 2023 [cited 2024 Aug 6];10. Available from: /pmc/articles/PMC10462056/
Napodano C, Pocino K, Rigante D, Stefanile A, Gulli F, Marino M, et al. Free light chains and autoimmunity. Autoimmun Rev. 2019;18:484–92.
doi: 10.1016/j.autrev.2019.03.003
pubmed: 30844547
Einarsson Long T. Revised definition of free light chains in serum and light chain monoclonal gammopathy of undetermined significance: results of the istopmm study. ASH; 2023.
Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, Offord JR, et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med [Internet]. 2006;354:1362–9.
doi: 10.1056/NEJMoa054494
pubmed: 16571879
Kyle RA, Buadi F, Vincent Rajkumar S. Management of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). Oncology (Williston Park) [Internet]. 2011;25:578.
Clinical course and management of monoclonal gammopathy of undetermined significance - UpToDate [Internet]. [cited 2023 Nov 2]. Available from: https://www-uptodate-com.ezproxy.bgu.ac.il/contents/clinical-course-and-management-of-monoclonal-gammopathy-of-undetermined-significance?search=management%20MGUS&source=search_result&selectedTitle=1~62&usage_type=default&display_rank=1
Pearson DS, McEvoy DS, Murali MR, Dighe AS. Use of clinical decision support to improve the laboratory evaluation of monoclonal gammopathies. Am J Clin Pathol [Internet]. 2023;159:192–204.
doi: 10.1093/ajcp/aqac151
pubmed: 36622340
van de Donk NWCJ, Palumbo A, Johnsen HE, Engelhardt M, Gay F, Gregersen H, et al. The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network. Haematologica [Internet]. 2014;99:984–96.
doi: 10.3324/haematol.2013.100552
pubmed: 24658815
Cohen Y. Smoldering multiple myeloma progressing to active multiple myeloma vs de-novo active multiple myeloma – a comparison of disease characteristics, organ involvement and outcomes in a real-life multicenter retrospective cohort study. ASH; 2023.
Dispenzieri A, Katzmann JA, Kyle RA, Larson DR, Melton LJ, Colby CL, et al. Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance (LC-MGUS): a newly defined entity. Lancet [Internet]. 2010;375:1721.
doi: 10.1016/S0140-6736(10)60482-5
pubmed: 20472173
Kyle RA, Rajkumar SV. Monoclonal gammopathy of undetermined significance and smouldering multiple myeloma: emphasis on risk factors for progression. Br J Haematol [Internet]. 2007;139:730–43.
doi: 10.1111/j.1365-2141.2007.06873.x
pubmed: 18021088
Kyle RA, Larson DR, Therneau TM, Dispenzieri A, Kumar S, Cerhan JR, et al. Long-term follow-up of monoclonal gammopathy of undetermined significance. N Engl J Med [Internet]. 2018;378:241–9.
doi: 10.1056/NEJMoa1709974
pubmed: 29342381
Kaur J, Valisekka SS, Hameed M, Bandi PS, Varma S, Onwughalu CJ, et al. Monoclonal Gammopathy of undetermined significance: a comprehensive review. Clin Lymphoma Myeloma Leuk. 2023;23:e195-212.
doi: 10.1016/j.clml.2023.02.004
pubmed: 36966041
Gaudio A, Xourafa A, Rapisarda R, Zanoli L, Signorelli SS, Castellino P. Hematological Diseases And Osteoporosis. Int J Mol Sci. 2020;21:3538.
doi: 10.3390/ijms21103538
pubmed: 32429497
pmcid: 7279036
Musto P, Engelhardt M, Caers J, Bolli N, Kaiser M, van de Donk N, et al. European Myeloma Network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. Hyde. Haematologica [Internet]. 2021;106:2799–812.
doi: 10.3324/haematol.2021.278519
pubmed: 34261295
Snozek CLH, Katzmann JA, Kyle RA, Dispenzieri A, Larson DR, Therneau TM, et al. Prognostic value of the serum free light chain ratio in newly diagnosed myeloma: proposed incorporation into the international staging system. Leuk Off J Leuk Soc Am Leuk Res Fund UK [Internet]. 2008;22:1933.
Singh MK, Paswan V, Dwivedi S, Gupta R, Rahman K, Chandra D, et al. An analysis of M-protein in plasma cell dyscrasia patients identifies that IgG lambda subtype is more commonly associated with normal serum free light chain (SFLC) ratio. Indian J Clin Biochem. 2022;37:466–72.
doi: 10.1007/s12291-021-01017-5
pubmed: 36262785
Murray DL, Puig N, Kristinsson S, Usmani SZ, Dispenzieri A, Bianchi G, et al. Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: an international myeloma working group mass spectrometry committee report. Blood Cancer J [Internet]. 2021 [cited 2024 Aug 8];11. Available from: /pmc/articles/PMC7873248/
Wilhite D, Arfa A, Cotter T, Savage NM, Bollag RJ, Singh G. Multiple myeloma: detection of free monoclonal light chains by modified immunofixation electrophoresis with antisera against free light chains. Pract Lab Med [Internet]. 2021 [cited 2024 Aug 8];27. Available from: /pmc/articles/PMC8521168/
Uljon SN, Simmons DP, Rudolf JW, Baron JM, Dutta S, McEvoy DS, et al. Validation and implementation of an ordering alert to improve the efficiency of monoclonal gammopathy evaluation. Am J Clin Pathol [Internet]. 2020;153:396–406.
doi: 10.1093/ajcp/aqz180
pubmed: 31776551